• Equine Clinical Immunology offers comprehensive information on equine immunological disorders.

    • Provides a complete, equine-specific reference on clinical immunology
    • Focuses on clinically relevant information for the diagnosis and treatment of horses with immune disorders
    • Illustrates the concepts discussed using drawings, photographs, and tables
    • Presents key concepts, clinical assessment information, and treatment approaches in text boxes for ease of use
    • Offers a practical, clinically oriented approach ideal for equine specialists

  • Contributors, ix

    Preface, xi

    1 The Immune System, 1
    M. Julia B. Felippe

    1.1 Definition, 1

    1.2 The organs of the immune system, 1

    1.3 The immune cells and soluble molecules, 2

    1.4 B and T cell activation in lymphoid tissues, 6

    1.5 When the immune response goes wrong, 9

    References, 10

    2 The Immune System of the Young Horse, 11
    Rebecca L. Tallmadge

    2.1 Definition, 11

    2.2 Equine immune system development, 11

    2.3 Unique susceptibilities and disorders of young horses, 16

    2.4 Vaccinology teaches about neonatal immunity, 18

    References, 18

    3 The Immune System of the Older Horse, 23
    Amanda A. Adams and David W. Horohov

    3.1 Definition, 23

    3.2 Clinical conditions associated with aging, 23

    3.3 Immunosenescence and vaccination, 23

    3.4 Nutrition in enhancing immunity in the old horse, 26

    3.5 Conclusion, 27

    References, 27

    4 Anaphylaxis, 31
    Rolfe M. Radcliffe

    4.1 Definition, 31

    4.2 Signalment and clinical signs, 31

    4.3 Immunologic mechanisms and etiologic associations, 32

    4.4 Diagnostics, 33

    4.5 Treatment, 34

    4.6 Prevention, 36

    4.7 Prognosis and clinical outcomes, 37

    References, 37

    5 Allergy, 39
    Bettina Wagner

    5.1 Definition, 39

    5.2 Culicoides hypersensitivity, 39

    5.3 Urticaria, 43

    5.4 Recurrent airway obstruction, 44

    References, 44

    6 Immune-Mediated Cytopenias, 47
    Thomas J. Divers

    6.1 Definition, 47

    6.2 Immune-mediated hemolytic anemia, 47

    6.3 Immune-mediated thrombocytopenia, 50

    6.4 Immune-mediated neutropenia, 53

    References, 54

    7 Bullous Diseases of the Skin and Mucosa, 55
    Jeanine Peters-Kennedy and Rebecca E. Ruby

    7.1 Definition, 55

    7.2 Immune-mediated bullous dermatoses, 55

    7.3 Pemphigus complex, 57

    7.4 Cutaneous adverse drug reactions, 61

    7.5 Erythema multiforme, 62

    7.6 Lupus erythematosus, 64

    References, 65

    8 Serum Sickness, 69
    Lais R.R. Costa

    8.1 Definition, 69

    8.2 Signalment and clinical signs, 69

    8.3 Immunologic mechanisms and etiologic associations, 69

    8.4 Diagnostics, 71

    8.5 Treatment and prevention, 71

    References, 72

    9 Vasculitis, 73
    James S. W. Prutton and Nicola Pusterla

    9.1 Definition, 73

    9.2 Signalment and clinical signs, 73

    9.3 Immunologic mechanisms and etiologic associations, 73

    9.4 Diagnostics, 75

    9.5 Treatment, 75

    9.6 Thrombophlebitis, 75

    9.7 Pastern and cannon leukocytoclastic vasculitis, 76

    9.8 Drug-induced vasculitis, 76

    9.9 Photo-activated vasculitis (photodynamic drugs), 77

    9.10 Strongylus vulgaris, 77

    9.11 Equine granulocytic anaplasmosis, 77

    9.12 Equine viral arteritis, 78

    9.13 Equine herpesvirus-1, 78

    9.14 African horse sickness, 78

    References, 79

    10 Purpura Hemorrhagica, 83
    Laszlo M. Hunyadi and Nicola Pusterla

    10.1 Definition, 83

    10.2 Signalment and clinical signs, 83

    10.3 Immunologic mechanisms and etiologic associations, 83

    10.4 Diagnostics, 84

    10.5 Treatment and prevention, 85

    References, 86

    11 Glomerulonephritis, 87
    M. Julia B. Felippe

    11.1 Definition, 87

    11.2 Signalment and clinical signs, 87

    11.3 Immunologic mechanisms and etiologic associations, 87

    11.4 Diagnostics, 88

    11.5 Treatment and prognosis, 88

    References, 88

    12 Inflammatory and Immune-Mediated Muscle Disorders, 91
    Sian Durward-Akhurst and Stephanie J. Valberg

    12.1 Definition, 91

    12.2 Infarctive purpura hemorrhagica, 91

    12.3 Rhabdomyolysis associated with Streptococcus equi, 93

    12.4 Immune-mediated myositis in Quarter Horse-related breeds, 94

    12.5 Systemic calcinosis, 96

    12.6 Uncharacterized immune-mediated and inflammatory myopathies, 97

    12.7 Sarcocystis myositis, 97

    References, 98

    13 Granulomatous Diseases, 101
    Lais R.R. Costa

    13.1 Definition, 101

    13.2 Signalment and clinical signs, 101

    13.3 Immunologic mechanisms and etiologic associations, 101

    13.4 Diagnostics, 104

    13.5 Treatment and prevention, 105

    13.6 Types of cell-mediated hypersensitivity reactions, 105

    References, 110

    14 Chronic Inflammatory Bowel Disease, 113
    Gillian A. Perkins

    14.1 Definition, 113

    14.2 Signalment and clinical signs, 113

    14.3 Immunologic mechanisms and etiologic associations, 113

    14.4 Diagnostics, 115

    14.5 Treatment and prognosis, 116

    References, 117

    15 Recurrent Uveitis, 121
    Brian C. Gilger

    15.1 Definition, 121

    15.2 Signalment and clinical signs, 121

    15.3 Immunologic mechanisms and etiologic associations, 121

    15.4 Diagnostics, 123

    15.5 Treatment and prevention, 124

    15.6 Prognosis and clinical outcomes, 124

    References, 125

    16 Recurrent Airway Obstruction and Summer Pasture-Associated Obstructive Pulmonary Disease, 127
    Michela Bullone and Jean-Pierre Lavoie

    16.1 Definition, 127

    16.2 Signalment and clinical signs, 127

    16.3 Immunologic mechanisms and etiologic associations, 128

    16.4 Diagnostics, 134

    16.5 Treatments and prevention, 136

    References, 137

    17 Inflammatory Airway Disease, 145
    Mathilde Leclère and Jean-Pierre Lavoie

    17.1 Definition, 145

    17.2 Signalment and clinical signs, 145

    17.3 Immunologic mechanisms and etiologic associations, 145

    17.4 Types of bronchoalveolar lavage fluid inflammation and cytokine profile, 147

    17.5 Links between IAD and heaves, 148

    17.6 Links between IAD and EIPH, 148

    17.7 Diagnostics, 148

    17.8 Treatment and prevention, 149

    17.9 Prognosis and clinical outcomes, 150

    References, 150

    18 Inflammation, Endotoxemia and Systemic Inflammatory Response Syndrome, 153
    Erin L. McConachie and Kelsey A. Hart

    18.1 Definition, 153

    18.2 Signalment and clinical signs, 154

    18.3 Immunologic mechanisms and etiologic associations, 155

    18.4 Multi-systemic response triggered by inflammatory mediators, 157

    18.5 Diagnostics, 160

    18.6 Treatment, 162

    18.7 Prognosis and clinical outcome, 166

    References, 166

    19 Leukemia, 173
    Tracy Stokol

    19.1 Definition, 173

    19.2 Classification of leukemias, 173

    19.3 Specialized diagnostic techniques for leukemia, 173

    19.4 Chronic leukemia, 175

    19.5 Acute leukemia, 177

    References, 179

    20 Lymphoma, 181
    SallyAnne L. Ness

    20.1 Definition, 181

    20.2 Signalment and clinical signs, 181

    20.3 Forms of equine lymphoma, 182

    20.4 Immunologic mechanisms and etiologic associations, 183

    20.5 Diagnostics, 183

    20.6 Classification of lymphomas, 185

    20.7 Prognosis and treatment, 186

    20.8 Monitoring, 189

    References, 189

    21 Immunodeficiencies, 193
    M. Julia B. Felippe

    21.1 Definition, 193

    21.2 Classification of immunodeficiencies, 194

    References, 202

    22 Immunologic Testing, 205
    M. Julia B. Felippe

    22.1 Definition, 205

    22.2 Types of immunologic testing, 205

    References, 211

    23 Non-steroidal Anti-inflammatories, 213
    Michelle H. Barton

    23.1 Definition, 213

    23.2 Non-steroidal anti-inflammatory drugs, 213

    References, 228

    24 Immunosuppressive Therapy, 237
    M. Julia B. Felippe

    24.1 Definition, 237

    24.2 Types of immunosuppressive drugs, 237

    References, 240

    25 Immunomodulators, 243
    Elizabeth G. Davis

    25.1 Definition, 243

    25.2 Immunologic mechanisms, 243

    25.3 Commercially available immunostimulants for use in horses, 244

    References, 249

    26 Immunoglobulin Therapy, 251
    Elizabeth G. Davis

    26.1 Definition, 251

    26.2 Immunologic mechanisms, 251

    References, 254

    27 Plasmapheresis, 257
    Nathan M. Slovis

    27.1 Definition, 257

    27.2 Methods for preparing plasma products, 257

    27.3 Apheresis, 258

    27.4 Therapeutic plasmapheresis, 258

    27.5 Complications of therapeutic plasmapheresis, 260

    References, 260

    28 Principles of Vaccination, 263
    Noah D. Cohen and Angela I. Bordin

    28.1 Definition, 263

    28.2 Efficacy and effectiveness of vaccines, 263

    28.3 Safety of vaccines, 271

    28.4 Key knowledge-gaps in equine vaccinology, 273

    28.5 Protocols for vaccination, 275

    References, 276

    29 Types of Vaccines, 279
    Angela I. Bordin and Noah D. Cohen

    29.1 Definition, 279

    29.2 Immunologic mechanisms, 279

    29.3 Immune responses to vaccination, 282

    29.4 Routes of vaccination, 284

    29.5 Adjuvants and vaccine delivery systems, 285

    29.6 Important diseases with unavailable effective vaccines, 285

    References, 286

    30 Transplantation Immunology, 289
    Rebecca L. Tallmadge

    30.1 Definition, 289

    30.2 Equine MHC genes: genomic organization and variation, 289

    30.3 Determining equine MHC haplotypes, 290

    30.4 Immunosuppression and engraftment, 291

    30.5 Graft rejection, 292

    30.6 Current transplantation applications, 293

    References, 294

    31 Mesenchymal Stem Cell Therapy, 297
    Gerlinde R. Van de Walle, Catharina De Schauwer and Lisa A. Fortier

    31.1 Definition, 297

    31.2 Regenerative functions of mesenchymal stem cells, 297

    31.3 Immunologic mechanisms and associations, 298

    31.4 Sources of equine mesenchymal stem cells, 299

    31.5 Characterization of equine mesenchymal stem cells, 300

    31.6 Applications of equine mesenchymal stem cells in equine regenerative medicine, 302

    References, 306

    32 Hematopoietic Stem Cell Transplantation, 311
    M. Julia B. Felippe

    32.1 Definition, 311

    32.2 Hematopoietic stem cell sources, 311

    32.3 Pre-transplantation conditioning, 313

    32.4 Post-transplantation immunosuppression, 313

    32.5 Hematopoietic stem cell transplantation in the horse, 313

    References, 315

    Index, 317

  • M. Julia B. Felippe, MedVet, MSc, PhD, DACVIM, is an Associate Professor of Large Animal Medicine and Veterinary Curriculum Director at Cornell University’s College of Veterinary Medicine in Ithaca, New York, USA.

info